Biophytis S.A. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BPTSY Over the counter 2834 www.biophytis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biophytis S.A.

Biophytis Targets Mobility Restoration in Patients with Obesity - Apr 22nd, 2025 5:00 am
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity - Apr 9th, 2025 5:30 am
Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity - Mar 24th, 2025 6:30 am
Biophytis Revolutionizes Sarcopenia - Mar 17th, 2025 6:00 am
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - Mar 14th, 2025 12:35 pm
Life Sciences Investor Forum Agenda Announced for March 13th - Mar 12th, 2025 5:12 pm
Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR) - Feb 25th, 2025 6:00 am
Biophytis Unveils Its Outlook Strategies for 2025 - Feb 11th, 2025 6:00 am
Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference - Jan 27th, 2025 6:00 am
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China - Jan 21st, 2025 6:00 am
Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101 - Jan 14th, 2025 6:00 am
Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities - Sep 30th, 2024 9:48 pm
Immunis to use MRI-based AI muscle analysis for sarcopenia trial - Jul 26th, 2024 3:03 pm
Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia - Jul 22nd, 2024 6:30 am
FDA approves Biophytis’ Phase II OBA obesity study - Jul 12th, 2024 8:32 am
Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity - Jul 11th, 2024 6:40 am
Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million - Jun 20th, 2024 5:20 am
Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity - Jun 10th, 2024 6:40 am
Combined General Meeting of June 24, 2024 - Jun 7th, 2024 6:00 am
Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity - May 14th, 2024 5:20 am